Literature DB >> 12838663

[The presence of hepatitis C virus (HCV) infection in hemodialysis patients and determination of HCV genotype distribution].

Gülendam Bozdayi1, Seyyal Rota, Hasibe Verdi, Ulver Derici, Sükrü Sindel, Musa Bali, Turgay Başay.   

Abstract

The aim of this study was the investigation of hepatitis C virus (HCV) RNA by reverse transcriptase-polymerase chain reaction (RT-PCR), in hemodialysis patients in order to detect HCV infection, and the determination of virus genotypes in HCV positive patients. A total of 94 patients, 44 female and 50 male (mean age: 49 +/- 17 years old), who were included in hemodialysis program between 1987-1999 (0-13 years) in the Hemodialysis Units of Gazi University, School of Medicine and Ankara Etlik Hospital of Social Insurance Society, were enrolled in the study. Anti-HCV was found positive in 41 patients (43.6%), while HCV-RNA was positive in 36 patients (38.3%). Thirty three of the patients were positive for both anti-HCV and HCV-RNA, 8 were anti-HCV positive HCV-RNA negative, and 3 were anti-HCV negative HCV-RNA positive. HCV was genotyped by Restriction Fragment Length Polymorphism (RFLP) method in 36 HCV-RNA positive patients, and 28 yielded genotype 1b, and 8 showed genotype 1a pattern. PCR products from 5'UTR of HCV-RNA isolated from two patients were also sequenced to confirm the results of RFLP study. The rate of anti-HCV and HCV-RNA positivity was detected statistically higher in patients who exposed hemodialysis longer than 24 months, and in hemodialysis patients who had blood transfusion than the other groups. As a result, our findings supported that the periodic follow-up of HCV-RNA, in addition to anti-HCV would be useful for hemodialysis patients, and genotyping of HCV for the epidemiologic data.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12838663

Source DB:  PubMed          Journal:  Mikrobiyol Bul        ISSN: 0374-9096            Impact factor:   0.622


  7 in total

1.  Virological responses of pegylated interferon alpha-2a treatment in hemodialysis patients infected with hepatitis C.

Authors:  Şükran Köse; Süheyla Serin Senger; Gürsel Ersan; Gülsün Çavdar
Journal:  Clin Exp Nephrol       Date:  2012-07-20       Impact factor: 2.801

Review 2.  Potential for human immunodeficiency virus parenteral transmission in the Middle East and North Africa: an analysis using hepatitis C virus as a proxy biomarker.

Authors:  Yousra A Mohamoud; F DeWolfe Miller; Laith J Abu-Raddad
Journal:  World J Gastroenterol       Date:  2014-09-28       Impact factor: 5.742

Review 3.  Hepatitis C virus infection in the Middle East and North Africa "MENA" region: injecting drug users (IDUs) is an under-investigated population.

Authors:  S Ramia; N M Melhem; K Kreidieh
Journal:  Infection       Date:  2012-01-12       Impact factor: 3.553

4.  Prevalence of hepatitis C virus (HCV) genotypes among positive UAE patients.

Authors:  Mubarak S Alfaresi
Journal:  Mol Biol Rep       Date:  2010-11-20       Impact factor: 2.316

5.  Genotypes of hepatitis C virus (HCV) among positive Lebanese patients: comparison of data with that from other Middle Eastern countries.

Authors:  A I Sharara; S Ramia; F Ramlawi; J Eid Fares; S Klayme; R Naman
Journal:  Epidemiol Infect       Date:  2006-07-19       Impact factor: 2.451

Review 6.  Hepatocellular carcinoma in the world and the middle East.

Authors:  H Poustchi; Sg Sepanlou; S Esmaili; N Mehrabi; A Ansarymoghadam
Journal:  Middle East J Dig Dis       Date:  2010-01

Review 7.  The Distribution of Hepatitis C Virus Genotypes in Middle Eastern Countries: A Systematic Review and Meta-Analysis.

Authors:  Hossein Ghaderi-Zefrehi; Mohammad Gholami-Fesharaki; Heidar Sharafi; Farzin Sadeghi; Seyed Moayed Alavian
Journal:  Hepat Mon       Date:  2016-08-23       Impact factor: 0.660

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.